Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 19;15(1):88.
doi: 10.1186/s12974-018-1108-6.

MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature

S Jarius  1   2 , K Ruprecht  3 , J P Stellmann  4   5 , A Huss  6 , I Ayzenberg  7 , A Willing  4 , C Trebst  8 , M Pawlitzki  9 , A Abdelhak  6 , T Grüter  7 , F Leypoldt  10 , J Haas  11 , I Kleiter  7   12 , H Tumani  6   13 , K Fechner  14 , M Reindl  15 , F Paul  3   16   17 , B Wildemann  18   19
Affiliations
Review

MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature

S Jarius et al. J Neuroinflammation. .

Abstract

Background: Antibodies to human full-length myelin oligodendrocyte glycoprotein (MOG-IgG) as detected by new-generation cell-based assays have recently been described in patients presenting with acute demyelinating disease of the central nervous system, including patients previously diagnosed with multiple sclerosis (MS). However, only limited data are available on the relevance of MOG-IgG testing in patients with chronic progressive demyelinating disease. It is unclear if patients with primary progressive MS (PPMS) or secondary progressive MS (SPMS) should routinely be tested for MOG-IgG.

Objective: To evaluate the frequency of MOG-IgG among patients classified as having PPMS or SPMS based on current diagnostic criteria.

Methods: For this purpose, we retrospectively tested serum samples of 200 patients with PPMS or SPMS for MOG-IgG using cell-based assays. In addition, we performed a review of the entire English language literature on MOG-IgG published between 2011 and 2017.

Results: None of 139 PPMS and 61 SPMS patients tested was positive for MOG-IgG. Based on a review of the literature, we identified 35 further MOG-IgG tests in patients with PPMS and 55 in patients with SPMS; the only reportedly positive sample was positive just at threshold level and was tested in a non-IgG-specific assay. In total, a single borderline positive result was observed among 290 tests.

Conclusion: Our data suggest that MOG-IgG is absent or extremely rare among patients with PPMS or SPMS. Routine screening of patients with typical PPMS/SPMS for MOG-IgG seems not to be justified.

Keywords: Antibodies; Immunoglobulin G; MOG-IgG; Myelin oligodendrocyte glycoprotein (MOG); Neuromyelitis optica spectrum disorders (NMOSD); Primary chronic progressive MS (PPMS); Secondary chronic progressive MS (SPMS).

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study was approved by the institutional review boards of the participating centers. Patients gave written informed consent or were tested in an anonymised fashion as requested by the institutional review board of the University of Heidelberg.

Consent for publication

Not applicable.

Competing interests

BW has received research grants, speaking fees, and travel grants from Merck Serono, Biogen, Teva, Novartis, Sanofi Genzyme, Bayer Healthcare, the Klaus Tschira Stiftung, and the Dietmar Hopp Stiftung. JPS has received research grants and speaking fees from DFG, Biogen, and Genzyme not related to the present work. KR has received research grants from German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis), Novartis, Merck Serono, and the Charité Research Fund; honoraria for consultancy or speaking and travel reimbursement from Novartis, Bayer Healthcare, Biogen Idec, Merck Serono, sanofi-aventis/Genzyme, Teva Pharmaceuticals, and Guthy Jackson Charitable Foundation; all unrelated to the submitted work. MP received research grants, speaker honoraria, and travel/accommodation/meeting expenses from Novartis, and speaker honoraria from Genzyme, Biogen Idec., Merck Serono, and Roche. I.K. received honoraria for consultancy or speaking and travel reimbursement from Bayer Healthcare, Biogen, Chugai, Merck, Novartis, Roche, and Shire, and research support from Affectis, Biogen, Chugai and Diamed, all not related to the presented work. CT has received honoraria for consultation and expert testimony from Biogen Idec/GmbH, Genzyme GmbH and Novartis Pharmaceuticals; none of this interfered with the current report. K.F. is an employee of Euroimmun AG, Germany. FL is employed by a non-commercial academic institution (University Hospital Schlewsig-Holstein) offering antibody testing. The University Hospital and Medical University of Innsbruck (Austria; M.R.) receives payments for antibody assays (MOG, AQP4, and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Lübeck, Germany). All authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Reindl M, Jarius S, Rostasy K, Berger T. Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they? Curr Opin Neurol. 2017;30:295–301. doi: 10.1097/WCO.0000000000000446. - DOI - PubMed
    1. Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, Hummert MW, Trebst C, Pache F, Winkelmann A, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement—frequency, presentation and outcome. J Neuroinflammation. 2016;13:281. doi: 10.1186/s12974-016-0719-z. - DOI - PMC - PubMed
    1. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:280. doi: 10.1186/s12974-016-0718-0. - DOI - PMC - PubMed
    1. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13:279. doi: 10.1186/s12974-016-0717-1. - DOI - PMC - PubMed
    1. Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, Bellmann-Strobl J, Jarius S, Wildemann B, Reindl M, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13:282. doi: 10.1186/s12974-016-0720-6. - DOI - PMC - PubMed

Substances

LinkOut - more resources